05Sep
05Sep
Rapid Lyme disease test may be available in late 2020
The drawn-out process for diagnosing Lyme disease could become a thing of the past – good news for the thousands of people each year who get the tick-borne illness. A new detection test created by Ionica Sciences – located at Cornell’s McGovern Center life sciences incubator – has been sparked by a FuzeHub grant to begin moving from the laboratory bench into approvals, production and doctors’ offices. Read more >>
04Sep
$417K in grants awarded to New York colleges, manufacturers
A non-profit organization has awarded more than $400,000 worth of grants to manufacturers and colleges across New York state, including Ionica Sciences Read more >>
27Aug
Entelo Acquires ConveyIQ
Today, Entelo announces the acquisition of ConveyIQ, the leading provider of candidate engagement Software-as-a-Service solutions. Read more >>
23Aug
First Data adds new student loan reward benefit
First Data is offering a new benefit to 10,000 eligible employees to better enable them to pay down student loans. The financial services company is now allowing workers to earn performance rewards points to pay down their debt. The new program is offered in partnership with student loan benefit provider FutureFuel.io.Read more >>
23Aug
UMassFive Adds Student-loan Repayment Benefits as Employee Perk
UMassFive College Federal Credit Union announced it is bringing student-loan repayment benefits to its employees via a new partnership between Student Choice and FutureFuel.io. Read more >>
22Aug
Myomo Announces Technology Licensing Program for International Markets
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. Read more >>
20Aug
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>
17Aug
PlaceMe Acquires Bedly’s Boston Portfolio To Become The Largest Co-living Company In Boston
PlaceMe is acquiring the majority of Bedly’s Boston properties in a deal recently finalized. As a result, PlaceMe has become Boston’s largest co-living company, with over 150 fully-furnished bedrooms available for co-living. Read more >>
16Aug